此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Cardiovascular and Bone Mineral Markers in Dialysis Patients and Healthy Controls

2026年9月9日 更新者:Veysel Baran TOMAR、Gazi University

Prospective Comparative Evaluation of the Biochemical and Clinical Effects of Different Dialysis Modalities on Cardiovascular Status and Bone Mineral Metabolism

This observational study will compare cardiovascular status, bone mineral metabolism, systemic inflammation, body composition, functional status, quality of life, pruritus, and pain among patients receiving different renal replacement therapy modalities and healthy controls.

Adult participants will be included in four groups: maintenance hemodialysis, continuous ambulatory peritoneal dialysis, automated peritoneal dialysis, and healthy controls. No new treatment, drug, dialysis modality, or experimental device will be assigned as part of the study. Participants will continue their routine clinical care.

Serum interleukin-6 (IL-6), vascular cell adhesion molecule-1 (VCAM-1), fibroblast growth factor-23 (FGF-23), and sclerostin levels will be measured. Arterial stiffness will be assessed using pulse wave velocity (PWV), and body composition will be assessed using the Body Composition Monitor (BCM). Handgrip strength, quality of life, pruritus, and pain scores will also be evaluated.

The study will also explore correlations between biochemical biomarkers, arterial stiffness, body composition, and patient-reported outcomes. In the automated peritoneal dialysis group, objective treatment adherence will additionally be assessed using the Sharesource (Baxter/Vantive) cloud-based remote patient monitoring platform.

研究概览

地位

主动,不招人

详细说明

Patients with end-stage kidney disease receiving renal replacement therapy have a high burden of cardiovascular disease, chronic inflammation, mineral and bone metabolism abnormalities, altered body composition, impaired quality of life, pruritus, and pain. Hemodialysis and peritoneal dialysis differ in clearance patterns, fluid management, and treatment delivery, which may influence biochemical, vascular, nutritional, and patient-reported outcomes.

This is a single-center observational clinical study including adult patients receiving routine renal replacement therapy and healthy controls. Participants will not be assigned to any intervention by the study protocol. Hemodialysis, continuous ambulatory peritoneal dialysis (CAPD), and automated peritoneal dialysis (APD) treatments will continue according to routine clinical practice and the decisions of the treating physicians.

The study will include 100 participants in four groups: 40 patients receiving maintenance hemodialysis, 20 patients receiving CAPD, 20 patients receiving APD, and 20 healthy controls. Dialysis patients will be evaluated at baseline, Month 3, Month 6, and Month 12. Healthy controls will be evaluated at baseline only.

The main objective is to compare patients receiving different dialysis modalities and healthy controls in terms of bone mineral metabolism, systemic inflammation, endothelial dysfunction, arterial stiffness, body composition, functional status, quality of life, pruritus, and pain. Serum sclerostin and fibroblast growth factor-23 (FGF-23) will be evaluated as bone mineral metabolism biomarkers. Serum interleukin-6 (IL-6) and vascular cell adhesion molecule-1 (VCAM-1) will be evaluated as inflammatory and endothelial dysfunction-related biomarkers. These biomarkers will be measured using enzyme-linked immunosorbent assay (ELISA).

For hemodialysis patients, blood samples will be obtained immediately before a mid-week dialysis session through the existing vascular access. For CAPD patients, APD patients, and healthy controls, fasting venous blood samples will be obtained in the morning. Serum samples will be processed and stored according to laboratory procedures until batch analysis.

Arterial stiffness will be assessed using pulse wave velocity (PWV). Body composition and fluid status will be assessed by bioimpedance analysis using the Fresenius Body Composition Monitor (BCM). Body composition parameters will include overhydration, extracellular water to total body water ratio, intracellular water, lean tissue index, body cell mass. Handgrip strength will be measured as a functional parameter.

Patient-reported outcomes will be assessed using the Kidney Disease Quality of Life-36 (KDQOL-36), the Uremic Pruritus in Dialysis Patients (UP-Dial) questionnaire, and the Short-Form McGill Pain Questionnaire (SF-MPQ), as applicable. In healthy controls, kidney disease-specific questionnaire components will not be applied; instead, the 12-Item Short Form Health Survey (SF-12) will be used to assess general health-related quality of life.

The study will also evaluate correlations between molecular biomarkers, instrumental measurements, and clinical scores. Specifically, the relationships between elevated biomarker levels, increased arterial stiffness, altered body composition, lower quality of life, pruritus, and pain burden will be explored.

As an additional objective, objective treatment adherence will be assessed in the APD group using data transferred from home cycler devices to the Sharesource (Baxter/Vantive) cloud-based remote patient monitoring platform. Adherence-related variables will include the percentage of completed sessions, lost dwell time, differences between prescribed and delivered ultrafiltration, and device bypass or manual intervention alarms. Full treatment adherence will be defined as completion of at least 90% of the prescribed dialysis session number and total prescribed dialysis duration.

No additional invasive procedure will be performed other than standard blood sampling for biomarker measurements. Pulse wave velocity and body composition measurements are non-invasive and will be performed using devices used in routine clinical practice.

研究类型

观察性的

注册 (估计的)

100

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Ankara
      • Ankara、Ankara、土耳其(türkiye)、06500
        • Gazi University Faculty of Medicine, Department of Nephrology

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

取样方法

非概率样本

研究人群

Adult participants will be recruited from the Gazi University Faculty of Medicine nephrology outpatient clinic and dialysis units. The study population will include four cohorts: patients receiving maintenance hemodialysis, patients receiving continuous ambulatory peritoneal dialysis, patients receiving automated peritoneal dialysis, and healthy controls without known kidney disease. Dialysis patients must have been receiving regular dialysis treatment for at least 6 months. Healthy controls will have no known kidney disease, systemic inflammatory disease, or active malignancy.

描述

Inclusion Criteria:

  • Age 18 to 80 years.
  • For dialysis cohorts: diagnosis of end-stage kidney disease and receiving maintenance hemodialysis or peritoneal dialysis.
  • For dialysis cohorts: receiving regular hemodialysis, continuous ambulatory peritoneal dialysis, or automated peritoneal dialysis for at least 6 months.
  • For healthy controls: no known kidney disease, with estimated glomerular filtration rate greater than 90 mL/min/1.73 m².
  • For healthy controls: no known systemic inflammatory disease or active malignancy.
  • Able to comply with planned study procedures, including pulse wave velocity measurement, Body Composition Monitor assessment, questionnaires, and biomarker measurements.
  • Able and willing to provide written informed consent.

Exclusion Criteria:

  • Inability to comply with study measurements or questionnaire assessments.
  • Refusal or inability to provide written informed consent.
  • Age younger than 18 years or older than 80 years.
  • Acute infection.
  • Recent major surgical intervention.
  • Active malignancy.
  • Terminal illness with limited life expectancy.
  • Mental, cognitive, physical, or clinical condition preventing participation in study procedures.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Maintenance Hemodialysis
Adult patients with end-stage kidney disease who have been receiving maintenance hemodialysis for at least 6 months. Participants in this cohort will continue their routine hemodialysis treatment three times weekly according to standard clinical practice. No intervention will be assigned by the study protocol. Blood samples, pulse wave velocity, body composition measurements, handgrip strength, and patient-reported outcome assessments will be performed at baseline, Month 3, Month 6, and Month 12.
Continuous Ambulatory Peritoneal Dialysis
Adult patients with end-stage kidney disease who have been receiving continuous ambulatory peritoneal dialysis (CAPD) for at least 6 months. Participants in this cohort will continue their routine CAPD treatment according to standard clinical practice. No intervention will be assigned by the study protocol. Blood samples, pulse wave velocity, body composition measurements, handgrip strength, and patient-reported outcome assessments will be performed at baseline, Month 3, Month 6, and Month 12.
Automated Peritoneal Dialysis
Adult patients with end-stage kidney disease who have been receiving automated peritoneal dialysis (APD) for at least 6 months. Participants in this cohort will continue their routine APD treatment according to standard clinical practice. No intervention will be assigned by the study protocol. Blood samples, pulse wave velocity, body composition measurements, handgrip strength, and patient-reported outcome assessments will be performed at baseline, Month 3, Month 6, and Month 12. Objective treatment adherence will also be assessed using data transferred from home cycler devices to the Sharesource cloud-based remote patient monitoring platform.
Healthy Controls
Adult healthy controls without known kidney disease, systemic inflammatory disease, or active malignancy. Healthy controls will not receive any intervention assigned by the study protocol. Baseline blood samples, pulse wave velocity, body composition measurements, handgrip strength, pain assessment, and general health-related quality of life assessment using the 12-Item Short Form Health Survey (SF-12) will be performed. Healthy controls will be evaluated at baseline only and will not undergo longitudinal follow-up.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Serum Interleukin-6 (IL-6) Concentration
大体时间:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Serum interleukin-6 (IL-6) concentration will be measured using enzyme-linked immunosorbent assay (ELISA). Change in serum IL-6 concentration from baseline to Month 12 will be evaluated in dialysis cohorts, and baseline IL-6 concentrations will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Serum Vascular Cell Adhesion Molecule-1 (VCAM-1) Concentration
大体时间:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Serum vascular cell adhesion molecule-1 (VCAM-1) concentration will be measured using enzyme-linked immunosorbent assay (ELISA). Change in serum VCAM-1 concentration from baseline to Month 12 will be evaluated in dialysis cohorts, and baseline VCAM-1 concentrations will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Serum Sclerostin Concentration
大体时间:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Serum sclerostin concentration will be measured using enzyme-linked immunosorbent assay (ELISA). Change in serum sclerostin concentration from baseline to Month 12 will be evaluated in dialysis cohorts, and baseline sclerostin concentrations will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Serum Fibroblast Growth Factor-23 (FGF-23) Concentration
大体时间:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Serum fibroblast growth factor-23 (FGF-23) concentration will be measured using enzyme-linked immunosorbent assay (ELISA). Change in serum FGF-23 concentration from baseline to Month 12 will be evaluated in dialysis cohorts, and baseline FGF-23 concentrations will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.

次要结果测量

结果测量
措施说明
大体时间
Change in Pulse Wave Velocity (PWV) Measured in m/s
大体时间:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Pulse wave velocity (PWV) will be measured in meters per second (m/s) as a single parameter of arterial stiffness. Changes in PWV over time will be evaluated in dialysis cohorts, and baseline PWV values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Handgrip Strength Measured by Hand Dynamometer
大体时间:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Handgrip strength will be measured in kilograms (kg) using a hand dynamometer as a functional parameter. Changes in handgrip strength over time will be evaluated in dialysis cohorts, and baseline handgrip strength values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Kidney Disease Quality of Life-36 (KDQOL-36) Score
大体时间:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Health-related quality of life will be evaluated using the Kidney Disease Quality of Life-36 (KDQOL-36) questionnaire in dialysis cohorts. Changes in KDQOL-36 scores over time will be evaluated in hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis cohorts. Higher scores indicate better health-related quality of life and a better outcome.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Uraemic Pruritus in Dialysis Patients (UP-Dial) Score
大体时间:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Pruritus severity will be evaluated using the Uraemic Pruritus in Dialysis Patients (UP-Dial) scale in dialysis cohorts. The UP-Dial total score ranges from 0 to 56, with higher scores indicating more severe pruritus and a worse outcome.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Short-Form McGill Pain Questionnaire (SF-MPQ) Total Pain Rating Index Score
大体时间:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Pain will be evaluated using the Short-Form McGill Pain Questionnaire (SF-MPQ) total Pain Rating Index score. The SF-MPQ total Pain Rating Index score is calculated from 15 pain descriptors, each scored from 0 to 3, resulting in a total score range of 0 to 45. Higher scores indicate greater pain severity and a worse outcome. Changes over time will be evaluated in dialysis cohorts, and baseline values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Overhydration (OH) Measured by Body Composition Monitor
大体时间:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Overhydration (OH) will be measured in liters (L) using the Body Composition Monitor (BCM). Changes in OH over time will be evaluated in dialysis cohorts, and baseline OH values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Extracellular Water to Total Body Water Ratio (ECW/TBW)
大体时间:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
The extracellular water to total body water ratio (ECW/TBW) will be assessed using the Body Composition Monitor (BCM). Changes in ECW/TBW over time will be evaluated in dialysis cohorts, and baseline ECW/TBW values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Intracellular Water (ICW) Measured by Body Composition Monitor
大体时间:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Intracellular water (ICW) will be measured in liters (L) using the Body Composition Monitor (BCM). Changes in ICW over time will be evaluated in dialysis cohorts, and baseline ICW values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Lean Tissue Index (LTI) Measured by Body Composition Monitor
大体时间:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Lean tissue index (LTI) will be measured in kg/m² using the Body Composition Monitor (BCM). Changes in LTI over time will be evaluated in dialysis cohorts, and baseline LTI values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Body Cell Mass Measured by Body Composition Monitor
大体时间:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Body cell mass will be measured in kilograms (kg) using the Body Composition Monitor (BCM). Changes in body cell mass over time will be evaluated in dialysis cohorts, and baseline body cell mass values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月1日

初级完成 (估计的)

2027年7月1日

研究完成 (估计的)

2027年7月1日

研究注册日期

首次提交

2026年6月30日

首先提交符合 QC 标准的

2026年6月30日

首次发布 (实际的)

2026年7月7日

研究记录更新

最后更新发布 (实际的)

2026年9月14日

上次提交的符合 QC 标准的更新

2026年9月9日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data (IPD) are not planned to be shared publicly. The study is a single-center observational study with a limited number of participants, and the dataset may include sensitive clinical, laboratory, questionnaire, and treatment adherence data. All data will be stored in coded form and managed in accordance with institutional policies, ethical requirements, and applicable data protection regulations. De-identified aggregate results may be reported in scientific publications.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅